IGM Biosciences, Inc. Operating Lease, Payments
IGM Biosciences, Inc. reported Operating Lease, Payments of $8.35 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2025-03-06
- IGM Biosciences, Inc. operating lease, payments for the quarter ending 2021-12-31 was $1.11M, a 46.63% increase year-over-year.
- IGM Biosciences, Inc. operating lease, payments for the quarter ending 2021-09-30 was $1.09M, a 45.03% increase year-over-year.
- IGM Biosciences, Inc. operating lease, payments for the quarter ending 2021-06-30 was $853.00K, a 13.73% increase year-over-year.
- IGM Biosciences, Inc. operating lease, payments for the quarter ending 2021-03-31 was $761.00K, a 2.84% increase year-over-year.
- IGM Biosciences, Inc. operating lease, payments for fiscal 2024 was $8.35M, a 3.06% increase from fiscal 2023.
- IGM Biosciences, Inc. operating lease, payments for fiscal 2023 was $8.10M, a 46.00% increase from fiscal 2022.
- IGM Biosciences, Inc. operating lease, payments for fiscal 2022 was $5.55M, a 45.27% increase from fiscal 2021.
- IGM Biosciences, Inc. operating lease, payments for fiscal 2021 was $3.82M, a 27.22% increase from fiscal 2020.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $8.35M 10-K · filed 2025-03-06 | |||
| 2023-12-31 | $8.10M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $5.55M 10-K · filed 2025-03-06 | |||
| 2021-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $2.21M derived: sum of 2 quarters · filed 2024-03-07 | $3.06M derived: sum of 3 quarters · filed 2024-03-07 | $3.82M 10-K · filed 2024-03-07 |
| 2021-09-30 | $1.09M 10-Q · filed 2021-11-04 | $1.95M derived: sum of 2 quarters · filed 2021-11-04 | $2.71M 10-Q · filed 2021-11-04 | $3.47M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | $853.00K 10-Q · filed 2021-08-09 | $1.61M 10-Q · filed 2021-08-09 | $2.37M derived: sum of 3 quarters · filed 2023-03-30 | $3.13M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | $761.00K 10-Q · filed 2021-05-06 | $1.52M derived: sum of 2 quarters · filed 2023-03-30 | $2.27M derived: sum of 3 quarters · filed 2023-03-30 | $3.02M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | $757.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.51M derived: sum of 2 quarters · filed 2023-03-30 | $2.26M derived: sum of 3 quarters · filed 2023-03-30 | $3.00M 10-K · filed 2023-03-30 |
| 2020-09-30 | $755.00K 10-Q · filed 2021-11-04 | $1.50M derived: sum of 2 quarters · filed 2021-11-04 | $2.25M 10-Q · filed 2021-11-04 | $2.79M derived: sum of 4 quarters · filed 2022-03-29 |
| 2020-06-30 | $750.00K 10-Q · filed 2021-08-09 | $1.49M 10-Q · filed 2021-08-09 | $2.03M derived: sum of 3 quarters · filed 2022-03-29 | $2.45M derived: sum of 4 quarters · filed 2022-03-29 |
| 2020-03-31 | $740.00K 10-Q · filed 2021-05-06 | $1.28M derived: sum of 2 quarters · filed 2022-03-29 | $1.70M derived: sum of 3 quarters · filed 2022-03-29 | $2.05M derived: sum of 4 quarters · filed 2022-03-29 |
| 2019-12-31 | $544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $961.00K derived: sum of 2 quarters · filed 2022-03-29 | $1.31M derived: sum of 3 quarters · filed 2022-03-29 | $1.53M 10-K · filed 2022-03-29 |
| 2019-09-30 | $417.00K 10-Q · filed 2020-11-05 | $767.00K derived: sum of 2 quarters · filed 2020-11-05 | $983.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $350.00K 10-Q · filed 2020-08-06 | $566.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $216.00K 10-Q · filed 2020-05-07 |